Marshall Wace
ANTX icon

Marshall Wace’s AN2 Therapeutics ANTX Stock Holding History

Marshall Wace’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$60.5K Buy
+17,700
New +$36.5K ﹤0.01% 2957
2024
Q3 		– Sell
-96,111
Closed -$207K – 2469
2024
Q2 		$207K Buy
96,111
+13,613
+17% +$32.4K ﹤0.01% 2289
2024
Q1 		$268K Sell
82,498
-254,823
-76% -$2.77M ﹤0.01% 2152
2023
Q4 		$6.91M Sell
337,321
-379,460
-53% -$6.35M 0.01% 795
2023
Q3 		$11.5M Buy
+716,781
New +$8.12M 0.02% 609

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Marshall Wace's ANTX Position: Q1 2026 in Review

Marshall Wace opened a new position in AN2 Therapeutics (ANTX) in Q1 2026: 17,700 shares worth $60.5K. The stake represents ﹤0.01% of the portfolio and ranks #2957 among its holdings. This is a return to the name: Marshall Wace previously reported a position in ANTX as recently as Q2 2024.

Marshall Wace first reported a position in ANTX in Q3 2023 and has held it in 5 quarters since. The position peaked at $11.5M in Q3 2023. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • Marshall Wace held 17,700 shares of AN2 Therapeutics worth $60.5K as of Q1 2026.
  • AN2 Therapeutics was a new Marshall Wace position in Q1 2026.
  • AN2 Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2957 holding.
  • Marshall Wace first reported a position in AN2 Therapeutics in Q3 2023 and has held it in 5 quarters since.
  • Marshall Wace's AN2 Therapeutics position peaked at $11.5M in Q3 2023.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.